Wednesday, July 9, 2025
The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Expert Opinion
January 13, 2023
Expert opinion
Hematologic Malignancies/Opinion
Zuma Trial
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Kite, a Gilead Company, just released an update from the Zuma 7 trial stating statistically significant overall survival benefit for
March 23, 2023
Melanoma & Skin Cancer/Opinion
Neoadjuvant-Adjuvant or Adjuvant Only Pembrolizumab in Advanced Melanoma
By Dr. Radhika Kulkarni Henry Ford Cancer Institute On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published in the New England Journal of Medicine. This
March 20, 2023
CheckMate-722: Nivolumab plus Chemotherapy versus Chemotherapy in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer with Disease Progression after EGFR Tyrosine Kinase Inhibitors
By Dr. Dipesh Uprety Karmanos Cancer Institute While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the activity of immunotherapy in oncogene-addicted non-small cell lung cancer is
March 20, 2023
De-escalating Therapy in Human Papillomavirus-Related Oropharyngeal Cancer
By Dr. Tarik Hadid Wayne State University Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the only known hosts. There are around 200 subtypes of the virus that
March 9, 2023
The CALYPSO Study Tests the Combination of MET and PD-L1 Inhibition in Patients with Advanced Papillary Renal Cancer
By Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renal cancer (PRC), a disease characterized by aggressive features and a
March 7, 2023
Hematologic Malignancies/Opinion
Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma
By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a
February 27, 2023
Hematologic Malignancies/Opinion
KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?
By Dr. Harsh Parmar Hackensack Meridian Health In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,
February 17, 2023
Hematologic Malignancies/Opinion
FDA Approves Pemigatinib in Patients with Relapsed/Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Finally a Treatment Option for a Challenging Disease
By Dr. Abhishek A. Mangaonkar Mayo Clinic The phase 2 FIGHT-203 trial (NCT#03011372) studied 28 patients with relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. FGFR1 rearrangement should be suspected in patients who
February 7, 2023
Hematologic Malignancies/Opinion
Chemotherapy Free Ph+ ALL Induction? The Promise of Ponatinib plus Blinatumomab
Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Philadelphia positive acute lymphoblastic leukemia treatment has been driven by the combination of tyrosine kinase inhibitors targeting BCR-ABL in conjunction with
January 31, 2023
Hematologic Malignancies/Opinion
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the phase III AGILE trial reported in the New England Journal of Medicine, Pau
January 31, 2023
More from Perspectives
Share Article